• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4826896)   Today's Articles (6857)
For: Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, Roshal M, Maslak P, Davila M, Brentjens RJ, Sadelain M. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med 2018;378:449-459. [PMID: 29385376 PMCID: PMC6637939 DOI: 10.1056/nejmoa1709919] [Citation(s) in RCA: 1981] [Impact Index Per Article: 283.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Number Cited by Other Article(s)
1
Zhe N, Li Q, Huang N, Li H, Chen H, Zhu P. Hotspots evolution and frontiers of immunotherapy for the treatment of acute myeloid leukemia: A bibliometric analysis. Hum Vaccin Immunother 2025;21:2448888. [PMID: 39819314 DOI: 10.1080/21645515.2024.2448888] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2024] [Revised: 12/10/2024] [Accepted: 12/29/2024] [Indexed: 01/19/2025]  Open
2
Lysandrou M, Zeiser R. Strategies to enhance anti-leukaemia immunotherapy. Curr Opin Pharmacol 2025;82:102525. [PMID: 40267742 DOI: 10.1016/j.coph.2025.102525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2024] [Revised: 03/27/2025] [Accepted: 04/01/2025] [Indexed: 04/25/2025]
3
Zhao XS, Chen XT, Chang YJ. Stem cell transplantation indications for patients with acute leukemia determined by measurable residual disease: what we know and what we do not know. BLOOD SCIENCE 2025;7:e00229. [PMID: 40144893 PMCID: PMC11939945 DOI: 10.1097/bs9.0000000000000229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2024] [Accepted: 02/19/2025] [Indexed: 03/28/2025]  Open
4
Rafaeli N, Costa DM, Ledesma C, Jain N, Tewari P, Khouri I, Alatrash G, Short N, Jabbour E, Rezvani K, Alousi A, Popat U, Champlin R, Shpall E, Kebriaei P. Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia. CLINICAL LYMPHOMA, MYELOMA & LEUKEMIA 2025;25:e374-e377. [PMID: 39955258 DOI: 10.1016/j.clml.2025.01.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/11/2024] [Revised: 01/10/2025] [Accepted: 01/13/2025] [Indexed: 02/17/2025]
5
Jamil A, Qureshi Z, Siddique R, Altaf F, Jamil R, Wali N. A Meta-analysis on Effects of Chimeric Antigen Receptor T-cell Therapy in Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia. Am J Clin Oncol 2025;48:283-289. [PMID: 39956997 DOI: 10.1097/coc.0000000000001176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2025]
6
Yu XJ, Liu C, Hu SZ, Yuan ZY, Ni HY, Sun SJ, Hu CY, Zhan HQ. Application of CAR-T cell therapy in B-cell lymphoma: a meta-analysis of randomized controlled trials. Clin Transl Oncol 2025;27:2700-2709. [PMID: 39514165 DOI: 10.1007/s12094-024-03774-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2024] [Accepted: 10/18/2024] [Indexed: 11/16/2024]
7
Cheloni G, Karagkouni D, Pita-Juarez Y, Torres D, Kanata E, Liegel J, Avigan Z, Saldarriaga I, Chedid G, Rallis K, Miles B, Tiwari G, Kim J, Mattie M, Rosenblatt J, Vlachos IS, Avigan D. Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoire. Nat Commun 2025;16:4819. [PMID: 40410132 PMCID: PMC12102275 DOI: 10.1038/s41467-025-59904-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2024] [Accepted: 05/02/2025] [Indexed: 05/25/2025]  Open
8
Dai H, Xu S, Wang Z, Li Z, Cao J, Hu T, Zhou F. Quality of life and symptom burden among hematologic malignancy patients undergoing CAR-T therapy: a cross-sectional study. Sci Rep 2025;15:17763. [PMID: 40404866 PMCID: PMC12098898 DOI: 10.1038/s41598-025-02720-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2025] [Accepted: 05/15/2025] [Indexed: 05/24/2025]  Open
9
Lin Y, Xiao Z, Hu F, Zheng X, Zhang C, Wang Y, Liu Y, Huang D, Wang Z, Xia C, Weng Q, Zhang L, Zhao Y, Qi H, Shen Y, Chen Y, Zhang F, Wu J, Liu P, Xu J, Liu L, Zhu Y, Zhang J, Qian W, Liang A, Zhu X, Wang T, Zhang M, Wang J. Engineered CRO-CD7 CAR-NK cells derived from pluripotent stem cells avoid fratricide and efficiently suppress human T-cell malignancies. J Hematol Oncol 2025;18:57. [PMID: 40390054 PMCID: PMC12090657 DOI: 10.1186/s13045-025-01712-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2025] [Accepted: 05/09/2025] [Indexed: 05/21/2025]  Open
10
Hushmandi K, Imani Fooladi AA, Reiter RJ, Farahani N, Liang L, Aref AR, Nabavi N, Alimohammadi M, Liu L, Sethi G. Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines. Exp Hematol Oncol 2025;14:75. [PMID: 40382583 DOI: 10.1186/s40164-025-00662-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2025] [Accepted: 04/25/2025] [Indexed: 05/20/2025]  Open
11
Yu X, Li P, Feng H, Kang J, Li Y, Liu S. CD58 could be a leukemic marker in patients with relapsed/refractory B-cell acute lymphoblastic leukemia after multiline therapies. Am J Clin Pathol 2025;163:644-648. [PMID: 40253622 DOI: 10.1093/ajcp/aqae166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2024] [Accepted: 11/29/2024] [Indexed: 04/22/2025]  Open
12
Lei S, Gao Y, Wang K, Wu S, Zhu M, Chen X, Zhou W, Chen X, Zhang J, Duan X, Men K. An Implantable Double-Layered Spherical Scaffold Depositing Gene and Cell Agents to Facilitate Collaborative Cancer Immunotherapy. ACS NANO 2025;19:17653-17673. [PMID: 40304563 DOI: 10.1021/acsnano.5c01366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/02/2025]
13
Locke FL, Munoz JL, Tees MT, Lekakis LJ, de Vos S, Nath R, Stevens DA, Malik SA, Shouse GP, Hamadani M, Oluwole OO, Perales MA, Miklos DB, Fisher PW, Feng A, Navale L, Le Gall JB, Neelapu SS. Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies. J Clin Oncol 2025;43:1695-1705. [PMID: 39946666 PMCID: PMC12058369 DOI: 10.1200/jco-24-01933] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2024] [Revised: 01/17/2025] [Accepted: 01/31/2025] [Indexed: 04/16/2025]  Open
14
Wang D, Stevens G, Flotte TR. Gene therapy then and now: A look back at changes in the field over the past 25 years. Mol Ther 2025;33:1889-1902. [PMID: 40022444 DOI: 10.1016/j.ymthe.2025.02.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2025] [Revised: 02/25/2025] [Accepted: 02/25/2025] [Indexed: 03/03/2025]  Open
15
Gao M, Liu Y, Zhao L, Chen J, Wan W, Yuan Z, Li L, Huang Y, Wang Y, Zheng Y. Cell Surface-Tethered Nucleic Acid Therapeutics Program Robust and Tumor-Responsive Enhancement of Adoptive Cell Therapy. ADVANCED MATERIALS (DEERFIELD BEACH, FLA.) 2025:e2419969. [PMID: 40318090 DOI: 10.1002/adma.202419969] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/18/2024] [Revised: 04/05/2025] [Indexed: 05/07/2025]
16
Shah BD, Cassaday RD, Park JH, Houot R, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, O'Dwyer KM, Tzachanis D, Arellano ML, Lin Y, Baer MR, Schiller GJ, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Mao D, Adhikary S, Zhou L, Hadjivassileva T, Damico Khalid R, Ghobadi A, Oluwole OO. Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Leukemia 2025;39:1058-1068. [PMID: 40108332 PMCID: PMC12055586 DOI: 10.1038/s41375-025-02532-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2024] [Revised: 12/06/2024] [Accepted: 02/04/2025] [Indexed: 03/22/2025]
17
Qi S, Li J, Gu X, Zhang Y, Zhou W, Wang F, Wang W. Impacts of ageing on the efficacy of CAR-T cell therapy. Ageing Res Rev 2025;107:102715. [PMID: 40058461 DOI: 10.1016/j.arr.2025.102715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2025] [Revised: 02/19/2025] [Accepted: 03/02/2025] [Indexed: 03/17/2025]
18
Ito Y, Suzuki T, Shimomura M, Takenouchi K, Ohnuki K, Shoda K, Kenmochi Y, Yagyu S, Matsuura K, Hayashi R, Nakatsura T. Feasibility of Intratumoral Administration With EPHB4-CAR-T Cells for the Treatment of Oral Squamous Cell Carcinoma. Cancer Sci 2025;116:1227-1238. [PMID: 40029791 PMCID: PMC12044661 DOI: 10.1111/cas.70023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2024] [Revised: 01/13/2025] [Accepted: 02/05/2025] [Indexed: 05/02/2025]  Open
19
Canelo-Vilaseca M, Sabbah M, Di Blasi R, Cristinelli C, Sureda A, Caillat-Zucman S, Thieblemont C. Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma. Bone Marrow Transplant 2025;60:559-567. [PMID: 40148484 PMCID: PMC12061774 DOI: 10.1038/s41409-025-02539-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2024] [Revised: 09/29/2024] [Accepted: 02/17/2025] [Indexed: 03/29/2025]
20
Mulvey A, Trueb L, Coukos G, Arber C. Novel strategies to manage CAR-T cell toxicity. Nat Rev Drug Discov 2025;24:379-397. [PMID: 39901030 DOI: 10.1038/s41573-024-01100-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/08/2024] [Indexed: 02/05/2025]
21
Liu S, An L, Yin Z, Lin Y, Ling Z, Deng B, Yu X, Zheng Q, Zhao D, Wu T, Chang AH, Tong C. Five-year outcome of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantation. Haematologica 2025;110:1192-1196. [PMID: 39665213 PMCID: PMC12050930 DOI: 10.3324/haematol.2024.286534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2024] [Accepted: 12/05/2024] [Indexed: 12/13/2024]  Open
22
Han F, Jiang Z, Guo Q, Li Y, Li C, Liang X, Han L, Gallant RC, Hou M, Peng J, Xu M. CD19 chimeric antigen receptor-T cell therapy in murine immune thrombocytopenia. Br J Haematol 2025;206:1430-1442. [PMID: 40139759 DOI: 10.1111/bjh.20061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2024] [Accepted: 03/18/2025] [Indexed: 03/29/2025]
23
Wu S, Wei Y, Qiu Y, Ai K, Chen M, Wang H, Zhang H, Cen Q, Liao P, Ding X, Xie X, Li Y. Inhibition of VEGF signaling prevents exhaustion and enhances anti-leukemia efficacy of CAR-T cells via Wnt/β-catenin pathway. J Transl Med 2025;23:494. [PMID: 40307793 PMCID: PMC12044824 DOI: 10.1186/s12967-024-05907-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2024] [Accepted: 11/20/2024] [Indexed: 05/02/2025]  Open
24
Niu C, Wei H, Pan X, Wang Y, Song H, Li C, Qie J, Qian J, Mo S, Zheng W, Zhuma K, Lv Z, Gao Y, Zhang D, Yang H, Liu R, Wang L, Tu W, Liu J, Chu Y, Luo F. Foxp3 confers long-term efficacy of chimeric antigen receptor-T cells via metabolic reprogramming. Cell Metab 2025:S1550-4131(25)00218-9. [PMID: 40328248 DOI: 10.1016/j.cmet.2025.04.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/21/2023] [Revised: 10/14/2024] [Accepted: 04/14/2025] [Indexed: 05/08/2025]
25
Lu Y, Zhao F. Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy. Mol Cancer 2025;24:126. [PMID: 40289115 PMCID: PMC12036236 DOI: 10.1186/s12943-025-02334-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2025] [Accepted: 04/15/2025] [Indexed: 04/30/2025]  Open
26
Marcoux C, Kebriaei P. SOHO State of the Art Updates and Next Questions | Transplant in Adult Acute Lymphoblastic Leukemia. CLINICAL LYMPHOMA, MYELOMA & LEUKEMIA 2025:S2152-2650(25)00147-8. [PMID: 40383653 DOI: 10.1016/j.clml.2025.04.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/07/2025] [Revised: 04/21/2025] [Accepted: 04/22/2025] [Indexed: 05/20/2025]
27
De Angelis B, D’Amore ML, Lecot P, Neininger K, Lorrain M, Gambotti L, Dreuillet C, Courcault E, Chatterjee S, Delgado J, Galy A, Franz P, Rodriguez-Madoz JR, Cabrerizo Y, Richter A, Girvalaki C, Noviello M, Tassi E, Sanges C, Luu M, Hudecek M, Kremer A, Locatelli F, Negre H, Quintarelli C. European survey on CAR T-Cell analytical methods from apheresis to post-infusion immunomonitoring. Front Immunol 2025;16:1567582. [PMID: 40342422 PMCID: PMC12058815 DOI: 10.3389/fimmu.2025.1567582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2025] [Accepted: 03/24/2025] [Indexed: 05/11/2025]  Open
28
Mougiakakos D, Meyer EH, Schett G. CAR T cells in autoimmunity: game changer or stepping stone? Blood 2025;145:1841-1849. [PMID: 39700499 DOI: 10.1182/blood.2024025413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2024] [Revised: 11/19/2024] [Accepted: 12/11/2024] [Indexed: 12/21/2024]  Open
29
Gauthier J, Liang EC, Huang JJ, Kimble EL, Hirayama AV, Fiorenza S, Voutsinas JM, Wu Q(V, Jaeger-Ruckstuhl CA, Pender BS, Kirchmeier DR, Torkelson A, Braathen K, Basom R, Shadman M, Kopmar NE, Cassaday RD, Riddell SR, Maloney DG, Turtle CJ. Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL. Blood Adv 2025;9:1861-1872. [PMID: 39820359 PMCID: PMC12008683 DOI: 10.1182/bloodadvances.2024015314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2024] [Revised: 12/13/2024] [Accepted: 12/26/2024] [Indexed: 01/19/2025]  Open
30
Lei W, Liu H, Deng W, Chen W, Liang Y, Gao W, Yuan X, Guo S, Li P, Wang J, Tong X, Sun YE, Liang A, Qian W. Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial. NATURE CANCER 2025:10.1038/s43018-025-00940-3. [PMID: 40251398 DOI: 10.1038/s43018-025-00940-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/24/2023] [Accepted: 03/05/2025] [Indexed: 04/20/2025]
31
Shirzadian M, Moori S, Rabbani R, Rahbarizadeh F. SynNotch CAR-T cell, when synthetic biology and immunology meet again. Front Immunol 2025;16:1545270. [PMID: 40308611 PMCID: PMC12040928 DOI: 10.3389/fimmu.2025.1545270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2024] [Accepted: 03/28/2025] [Indexed: 05/02/2025]  Open
32
Nguyen KA, Liu Z, Davies JS, McIntosh CP, Draper LM, Norberg SM, Rae Z, Achar SR, Altan-Bonnet G, Zhang L, Wu X, Meyer TJ, Kelly MC, Taylor N, Hinrichs CS, Ishii K. CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses. SCIENCE ADVANCES 2025;11:eadq4297. [PMID: 40203088 PMCID: PMC11980841 DOI: 10.1126/sciadv.adq4297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/13/2024] [Accepted: 03/04/2025] [Indexed: 04/11/2025]
33
Shahid S, Prockop SE, Flynn GC, Mauguen A, White CO, Bieler J, McAvoy D, Hosszu K, Cancio MI, Jakubowski AA, Scaradavou A, Boelens JJ, Sauter CS, Perales MA, Giralt SA, Taylor C, Chaudhari J, Wang X, Rivière I, Sadelain M, Brentjens RJ, Kernan NA, O'Reilly RJ, Curran KJ. Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies. Blood Adv 2025;9:1644-1657. [PMID: 39908482 PMCID: PMC11995077 DOI: 10.1182/bloodadvances.2024015157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2024] [Revised: 12/10/2024] [Accepted: 12/31/2024] [Indexed: 02/07/2025]  Open
34
Badar T, Luger SM, Litzow MR. Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia. Blood 2025;145:1475-1484. [PMID: 39236292 DOI: 10.1182/blood.2023022921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2024] [Revised: 08/06/2024] [Accepted: 08/06/2024] [Indexed: 09/07/2024]  Open
35
Lussana F, Magnani CF, Galimberti S, Gritti G, Gaipa G, Belotti D, Cabiati B, Napolitano S, Ferrari S, Moretti A, Buracchi C, Borleri GM, Rambaldi B, Rizzuto G, Grassi A, Paganessi M, Meli C, Tettamanti S, Risca G, Pais G, Spinozzi G, Benedicenti F, Cazzaniga G, Capelli C, Gotti E, Introna M, Golay J, Montini E, Balduzzi A, Valsecchi MG, Dastoli G, Rambaldi A, Biondi A. Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation. Blood Cancer J 2025;15:54. [PMID: 40180925 PMCID: PMC11968829 DOI: 10.1038/s41408-025-01260-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2025] [Revised: 02/26/2025] [Accepted: 03/19/2025] [Indexed: 04/05/2025]  Open
36
Rampotas A, Roddie C. The present and future of CAR T-cell therapy for adult B-cell ALL. Blood 2025;145:1485-1497. [PMID: 39316713 DOI: 10.1182/blood.2023022922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2024] [Revised: 08/21/2024] [Accepted: 08/21/2024] [Indexed: 09/26/2024]  Open
37
Wachsmann TLA, Poortvliet T, Meeuwsen MH, Remst DFG, Toes MF, Wouters AK, Hagedoorn RS, Falkenburg JHF, Heemskerk MHM. CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells. Mol Ther 2025;33:1642-1658. [PMID: 40022447 PMCID: PMC11997489 DOI: 10.1016/j.ymthe.2025.02.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2024] [Revised: 01/10/2025] [Accepted: 02/25/2025] [Indexed: 03/03/2025]  Open
38
Cheng Y, Zhang J, Mu W, Ye S, Cheng J, Zhu L, Wang G, Cao Y, Li D, Hu G, Huang L, Wang J, Zhou J. Dasatinib-resistant universal CAR-T cells proliferate in the presence of host immune cells and exhibit antitumor activity. Mol Ther 2025;33:1535-1551. [PMID: 39935177 PMCID: PMC11997472 DOI: 10.1016/j.ymthe.2025.02.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2024] [Revised: 12/01/2024] [Accepted: 02/06/2025] [Indexed: 02/13/2025]  Open
39
Ikeda S, Hasegawa K, Kogue Y, Arimori T, Kawamoto R, Wibowo T, Yaga M, Inada Y, Uehara H, Matsubara M, Tachikawa M, Suga M, Kida S, Shibata K, Tsutsumi K, Fukushima K, Fujita J, Ueda T, Kusakabe S, Hino A, Ichii M, Hirose A, Nakamae H, Hino M, Nakao T, Inoue M, Yoshihara K, Yoshihara S, Ueda S, Tachi T, Kuroda H, Murakami K, Kijima N, Kishima H, Igashira E, Murakami M, Takiuchi T, Kimura T, Hiroshima T, Kimura T, Shintani Y, Imai C, Yusa K, Mori R, Ogino T, Eguchi H, Takeda K, Oji Y, Kumanogoh A, Takagi J, Hosen N. CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant. NATURE CANCER 2025;6:595-611. [PMID: 40128569 DOI: 10.1038/s43018-025-00934-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/23/2023] [Accepted: 02/19/2025] [Indexed: 03/26/2025]
40
Zhou Z, Chen Y, Ba Y, Xu H, Zuo A, Liu S, Zhang Y, Weng S, Ren Y, Luo P, Cheng Q, Zuo L, Zhu S, Zhou X, Zhang C, Chen Y, Han X, Pan T, Liu Z. Revolutionising Cancer Immunotherapy: Advancements and Prospects in Non-Viral CAR-NK Cell Engineering. Cell Prolif 2025;58:e13791. [PMID: 39731215 PMCID: PMC11969250 DOI: 10.1111/cpr.13791] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2024] [Revised: 10/14/2024] [Accepted: 11/28/2024] [Indexed: 12/29/2024]  Open
41
Daoudlarian D, Segot A, Latifyan S, Bartolini R, Joo V, Mederos N, Bouchaab H, Demicheli R, Abdelhamid K, Ferahta N, Doms J, Stalder G, Noto A, Mencarelli L, Mosimann V, Berthold D, Stravodimou A, Sartori C, Shabafrouz K, Thompson JA, Wang Y, Peters S, Pantaleo G, Obeid M. Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy. Ann Oncol 2025;36:444-459. [PMID: 39701282 DOI: 10.1016/j.annonc.2024.12.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2024] [Revised: 11/26/2024] [Accepted: 12/04/2024] [Indexed: 12/21/2024]  Open
42
Mousavi S, Khazaee-Nasirabadi MH, Seyedmehdi MS, Bazi A, Mirzaee Khalilabadi R. Natural killer cells: a new promising source for developing chimeric antigen receptor anti-cancer cells in hematological malignancies. Leuk Lymphoma 2025;66:594-616. [PMID: 39656564 DOI: 10.1080/10428194.2024.2438802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2024] [Revised: 11/18/2024] [Accepted: 12/01/2024] [Indexed: 12/17/2024]
43
Zhang Q, Dai J, Liu T, Rao W, Li D, Gu Z, Huang L, Wang J, Hou X. Targeting cardiac fibrosis with Chimeric Antigen Receptor-Engineered Cells. Mol Cell Biochem 2025;480:2103-2116. [PMID: 39460827 DOI: 10.1007/s11010-024-05134-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2024] [Accepted: 10/04/2024] [Indexed: 10/28/2024]
44
Grady CB, Li Y, Maude SL, Hexner EO, Frey NV, Porter DL, Hwang WT. Inconsistent Reporting and Definitions of Time-to-Event Endpoints in CAR T Clinical Trials: A Review. Transplant Cell Ther 2025;31:271.e1-271.e13. [PMID: 39603418 PMCID: PMC11957941 DOI: 10.1016/j.jtct.2024.11.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2024] [Revised: 11/05/2024] [Accepted: 11/17/2024] [Indexed: 11/29/2024]
45
Davila M, Lee SB, Kang YP, Boucher J, Mandula J, Roselli E, Chang D, Jimenez R, Kotani H, Reid K, Vazquez-Martinez J, Beatty N, Goala P, Sierra-Mondragon R, Liu M, Koomen J, Nguyen J, Hussaini M, Shaw T, Wang X, Faramand R, Jain M, Locke F, Rodriguez P, Sailer C, McSain S, Hamid S, Tariq M, Wang J, Abraham-Miranda J. CAR T cell-driven induction of iNOS in tumor-associated macrophages promotes CAR T cell resistance in B cell lymphoma. RESEARCH SQUARE 2025:rs.3.rs-3481746. [PMID: 40235478 PMCID: PMC11998770 DOI: 10.21203/rs.3.rs-3481746/v1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/17/2025]
46
Bours B, Masouridi-Levrat S. Is There (Still) a Place for Sequential Conditioning? Curr Oncol 2025;32:196. [PMID: 40277753 PMCID: PMC12025471 DOI: 10.3390/curroncol32040196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2025] [Revised: 03/21/2025] [Accepted: 03/24/2025] [Indexed: 04/26/2025]  Open
47
Saxena K, Hung SH, Ryu E, Singh S, Zhang Tatarata Q, Zeng Z, Wang Z, Konopleva MY, Yee C. BH3 mimetics augment cytotoxic T cell killing of acute myeloid leukemia via mitochondrial apoptotic mechanism. Cell Death Discov 2025;11:120. [PMID: 40140361 PMCID: PMC11947210 DOI: 10.1038/s41420-025-02375-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2024] [Revised: 01/29/2025] [Accepted: 02/24/2025] [Indexed: 03/28/2025]  Open
48
Yassin AAK, Banerji R, Bhattacharya B, Radinsky O, Hadad U, Kaufman B, Porgador A. Enhancing the Efficacy of CAR-T Cell Production Using BX795 and Rosuvastatin in a Serum-Free Medium. Int J Mol Sci 2025;26:2988. [PMID: 40243610 PMCID: PMC11988885 DOI: 10.3390/ijms26072988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2025] [Revised: 03/12/2025] [Accepted: 03/20/2025] [Indexed: 04/18/2025]  Open
49
Short NJ, Aldoss I, DeAngelo DJ, Konopleva M, Leonard J, Logan AC, Park J, Shah B, Stock W, Jabbour E. Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts. Blood Adv 2025;9:1442-1451. [PMID: 39853316 PMCID: PMC11960638 DOI: 10.1182/bloodadvances.2024015441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2024] [Revised: 01/09/2025] [Accepted: 01/09/2025] [Indexed: 01/26/2025]  Open
50
Huang Y, Wang H. Tonic signaling in CAR-T therapy: the lever long enough to move the planet. Front Med 2025:10.1007/s11684-025-1130-x. [PMID: 40117019 DOI: 10.1007/s11684-025-1130-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2024] [Accepted: 12/16/2024] [Indexed: 03/23/2025]
PrevPage 1 of 40 123453940Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Excel